All Stories

  1. Use of medical therapies before pulmonary endarterectomy in chronic thromboembolic pulmonary hypertension patients with severe hemodynamic impairment
  2. Pulmonary arterial hypertension in Latin America: epidemiological data from local studies
  3. Reperfusion in acute pulmonary thromboembolism
  4. Survival of patients with schistosomiasis-associated pulmonary arterial hypertension in the modern management era
  5. Association between six-minute walk distance and long-term outcomes in patients with pulmonary arterial hypertension: Data from the randomized SERAPHIN trial
  6. RV Fractional Area Change and TAPSE as Predictors of Severe Right Ventricular Dysfunction in Pulmonary Hypertension: A CMR Study
  7. Prognostic relevance of appropriate renal function evaluation in pulmonary arterial hypertension
  8. Pulmonary Arterial Hypertension-Related Morbidity Is Prognostic for Mortality
  9. Estimation of Stroke Volume and Stroke Volume Changes by Electrical Impedance Tomography
  10. Pulmonary Hypertension: Definition, Classification, and Diagnosis
  11. Challenging the concept of adding more drugs in pulmonary arterial hypertension
  12. Momentum
  13. Uncovering Small Secrets in Big Data Sets
  14. JBP and bibliometric índices
  15. Pulmonary hypertension in lymphangioleiomyomatosis: prevalence, severity and the role of carbon monoxide diffusion capacity as a screening method
  16. SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
  17. Macitentan Improves Health-Related Quality of Life for Patients With Pulmonary Arterial Hypertension
  18. 3rd GUIDELINE FOR PERIOPERATIVE CARDIOVASCULAR EVALUATION OF THE BRAZILIAN SOCIETY OF CARDIOLOGY
  19. Consolidating in the present, with an eye to the future
  20. Pulmonary arterial hypertension in schistosomiasis
  21. A global view of pulmonary hypertension
  22. New anticoagulants for the treatment of venous thromboembolism
  23. 2016 - a second step
  24. Respiratory therapy: a problem among children and adolescents with cystic fibrosis
  25. Usefulness of Cardiovascular Magnetic Resonance Indices to Rule In or Rule Out Precapillary Pulmonary Hypertension
  26. Exercise Capacity Long-Term after Arterial Switch Operation for Transposition of the Great Arteries
  27. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN
  28. Pulmonary artery enlargement in schistosomiasis associated pulmonary arterial hypertension
  29. The next 40 years
  30. Pulmonary hypertension in sickle cell disease
  31. Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension
  32. Biomarkers and Prognostic Indicators in Pulmonary Arterial Hypertension
  33. Bringing the JBP and its readers closer together
  34. Management of Pulmonary Arterial Hypertension
  35. What is new about Rio?
  36. Incidence of spontaneous subdural hematoma in incident cases of pulmonary arterial hypertension: a registry of cases occurring over a five-year period
  37. Pulmonary Arterial Hypertension in the Southern Hemisphere
  38. 2015-another step along the road in a 40-year journey...
  39. Effect of Macitentan on Hospitalizations
  40. Epidemiology and Disease Classification of Pulmonary Hypertension
  41. Skeletal Muscle Abnormalities in Pulmonary Arterial Hypertension
  42. Left ventricular dysfunction in patients with suspected pulmonary arterial hypertension
  43. Brazilian Journal of Pulmonology and Portuguese Journal of Pulmonology: Strengthening ties in respiratory science
  44. Effect of Bosentan and Sildenafil Combination Therapy on Morbidity and Mortality in Pulmonary Arterial Hypertension (PAH): Results From the COMPASS-2 Study
  45. Goal-oriented treatment of pulmonary arterial hypertension
  46. Quality of life as a prognostic marker in pulmonary arterial hypertension
  47. Lodenafil treatment in the monocrotaline model of pulmonary hypertension in rats
  48. New steps for the international consolidation of the Brazilian Journal of Pulmonology
  49. Reply
  50. Carbon monoxide diffusing capacity and the complexity of diagnosis in pulmonary arterial hypertension
  51. Correction
  52. Sildenafil for Noncompaction Cardiomyopathy Treatment in a Child: Case Report
  53. Immunopathological aspects of schistosomiasis-associated pulmonary arterial hypertension
  54. Updated Clinical Classification of Pulmonary Hypertension
  55. Association Between WHO Functional Class and Long-term Prognosis in Patients With Pulmonary Arterial Hypertension: Data From SERAPHIN, A Randomized Controlled Study of Macitentan
  56. Do parameters of cardiac function predict long-term outcomes in patients with pulmonary arterial hypertension? Data from SERAPHIN, a randomized controlled study of macitentan
  57. Effect of Macitentan on Long-term Outcomes in Patients With Pulmonary Arterial Hypertension (PAH): Subanalysis of SERAPHIN Comparing Incident and Prevalent Patient Populations Not Treated With Background PAH-Specific Therapy
  58. Idiopathic Pulmonary Arterial Hypertension
  59. Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
  60. Prevalence of Dyslipidemia in Children with Congenital Heart Disease
  61. Delayed Myocardial Enhancement by Cardiac Magnetic Resonance Imaging in Pulmonary Arterial Hypertension: A Marker of Severity of Disease
  62. Pulmonary arterial hypertension: bridging the present to the future
  63. Cardiac Magnetic Resonance Imaging: What Can It Add to Our Knowledge of the Right Ventricle in Pulmonary Arterial Hypertension?
  64. Comparação de dois modelos experimentais de hipertensão pulmonar
  65. Pulmonary Vascular Disorders
  66. The Role of Target Therapies in Schistosomiasis-Associated Pulmonary Arterial Hypertension
  67. Safety and efficacy of sitaxsentan 50 and 100 mg in patients with pulmonary arterial hypertension
  68. Biomarkers in Pulmonary Arterial Hypertension
  69. Title Page / Table of Contents / Foreword / Preface
  70. Schistosomiasis and Pulmonary Hypertension
  71. Schistosomiasis and pulmonary hypertension
  72. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease
  73. O papel dos exames de imagem na avaliação da circulação pulmonar
  74. Predicting Survival in Pulmonary Arterial Hypertension
  75. Letter by Montani et al Regarding Article, “Elevated Levels of Inflammatory Cytokines Predict Survival in Idiopathic and Familial Pulmonary Arterial Hypertension”
  76. Schistosomiasis and others in group 5
  77. The Role Of Target-Therapies In Schistosomiasis-Associated Pulmonary Arterial Hypertension
  78. From the authors:
  79. Diagnóstico e tratamento da hipertensão pulmonar: uma atualização
  80. Contemporary issues in pulmonary hypertension
  81. S152 Dexamethasone reverses established monocrotaline-induced pulmonary hypertension in rats and increases pulmonary BMPR2 expression
  82. Dual receptor blockade by bosentan: clinical experience in treatment of pulmonary hypertension
  83. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats
  84. Survival in Schistosomiasis-Associated Pulmonary Arterial Hypertension
  85. Letter by Dias et al Regarding Article, "Pulmonary Hypertensive Medical Therapy in Chronic Thromboembolic Pulmonary Hypertension Before Pulmonary Thromboendarterectomy"
  86. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era
  87. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension
  88. Predicting survival in pulmonary arterial hypertension: time to move forward
  89. Schistosomiasis associated pulmonary hypertension
  90. Reply
  91. Pneumomediastinum after sneezing
  92. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension
  93. Corticoide sistêmico como tratamento de primeira linha da hipertensão pulmonar secundária a síndrome POEMS
  94. Other Causes of PAH (Schistosomiasis, Porto-Pulmonary Hypertension and Hemolysis-Associated Pulmonary Hypertension)
  95. Diagnosis, Assessment, and Treatment of Non-Pulmonary Arterial Hypertension Pulmonary Hypertension
  96. Updated Clinical Classification of Pulmonary Hypertension
  97. Evaluating humidity recovery efficiency of currently available heat and moisture exchangers: a respiratory system model study
  98. Validação de um protocolo para o teste de caminhada de seis minutos em esteira para avaliação de pacientes com hipertensão arterial pulmonar
  99. Cardiopulmonary Manifestations of Hepatosplenic Schistosomiasis
  100. Trends in pulmonary arterial hypertension
  101. Automatic versus manual pressure support reduction in the weaning of post-operative patients: a randomized controlled trial
  102. Pulmonary hypertension therapy and COPD: still many questions to be answered
  103. Portopulmonary Hypertension
  104. Doença veno-oclusiva pulmonar: alternativas diagnósticas e terapêuticas
  105. Hipertensão pulmonar associada ao tromboembolismo pulmonar crônico: limitações diagnósticas
  106. Platelet-derived Growth Factor Expression and Function in Idiopathic Pulmonary Arterial Hypertension
  107. Clinical Outcomes of Pulmonary Arterial Hypertension in Carriers ofBMPR2Mutation
  108. Assessment of compliance in pulmonary arterial hypertension
  109. "PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH FENFLURAMINE EXPOSURE: REPORT OF 109 CASES". R. SOUZA, M. HUMBERT, B. SZTRYMF, X. JAIS, A. YAICI, J. LE PAVEC, F. PARENT, P. HERVE, F. SOUBRIER, O. SITBON AND G. SIMONNEAU. EUR RESPIR J 2008; 31: 343-348.
  110. Pulmonary arterial hypertension associated with fenfluramine exposure: report of 109 cases
  111. Pulmonary Hypertension
  112. Functional implications of BAL in the presence of restrictive or obstructive lung disease
  113. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension
  114. Intravenous Epoprostenol in Inoperable Chronic Thromboembolic Pulmonary Hypertension
  115. Dendritic cell recruitment in lesions of human and experimental pulmonary hypertension
  116. Pulmonary artery distensibility in pulmonary arterial hypertension: an MRI pilot study
  117. Effect of sitaxsentan treatment on quality of life in pulmonary arterial hypertension
  118. NT-proBNP as a tool to stratify disease severity in pulmonary arterial hypertension
  119. Endothelin-1/Endothelin-3 Ratio
  120. Tadalafil para o tratamento da hipertensão arterial pulmonar idiopática
  121. The Role of NT-proBNP as a Prognostic Marker in Pulmonary Hypertension
  122. Impacto de biópsia pulmonar a céu aberto na insuficiência respiratória aguda refratária
  123. Long term imatinib treatment in pulmonary arterial hypertension
  124. Aortopulmonary Window: A Rare Cause of Pulmonary Hypertension
  125. Características clínicas dos pacientes com hipertensão pulmonar em dois centros de referência em São Paulo
  126. The effect of massive weight loss on pulmonary function of morbid obese patients
  127. Systemic sclerosis and bone loss: the role of the disease and body composition
  128. Comparison of two flow generators with a noninvasive ventilator to deliver continuous positive airway pressure: a test lung study
  129. Acute vasodilator test in pulmonary arterial hypertension: Evaluation of two response criteria
  130. Heterogeneous Remodeling of Lung Vessels in Idiopathic Pulmonary Fibrosis
  131. Clinical response to sildenafil in pulmonary hypertension associated with Gaucher disease
  132. Effect of bosentan treatment on surrogate markers in pulmonary arterial hypertension
  133. N-terminal-pro-brain natriuretic peptide as a haemodynamic marker in idiopathic pulmonary arterial hypertension
  134. Ação da adenosina na circulação pulmonar de pacientes com hipertensão pulmonar primária
  135. Lesão por inalação de fumaça
  136. Tromboendarterectomia pulmonar em paciente com 80 anos de idade
  137. Diffuse panbronchiolitis: an underdiagnosed disease? Study of 4 cases in Brazil
  138. Mask mechanics and leak dynamics during noninvasive pressure support ventilation: a bench study